Vassallo, C., Canali, B., Fiorentino, F., Morelli, P., Ripoli, S. and Fioravanti, L. 2023. Brentuximab vedotin + AVD in cHL: cost impact on adverse events, toxicity, second malignancies, end-of-life and subsequent lines of therapy in Italy. AboutOpen. 10, 1 (Oct. 2023), 103–109. DOI:https://doi.org/10.33393/ao.2023.2609.